Abstracts Archive - Page 212 of 2425 - ACR Meeting Abstracts

Abstract Number: 0709 • ACR Convergence 2023
Survival of Adults with IgA Vasculitis
Alojzija Hocevar¹, JAKA OSTROVRŠNIK², vESNA JURČIĆ³, Matija Tomšič⁴ and Ziga Rotar⁵, ¹Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ²UKC Ljubljana, Ljubljana, Slovenia, ³University of Ljubljana, Medical Faculty, Institute of Pathology, Ljubljana, Slovenia, ⁴Department of Rheumatology, University Medical Centre LJubljana, Ljubljana, Slovenia, ⁵University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Data on survival of adults with IgA vasculitis (IgAV) are scarce. The aim of our study was to estimate for the first time the…
Abstract Number: 0710 • ACR Convergence 2023
The Association of IgA Vasculitis and Malignancy in Adults: A Systematic Review
Hila Ghersin¹, Michelle Toker², Urmi Khanna², Rachel Schwartz¹, Benedict Wu³ and Anand Kumthekar², ¹Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, ³Montefiore Medical Center, Bronx, NY
Background/Purpose: IgA vasculitis (IgAV) is associated with malignancy in adult patients [1,2]. The clinical characteristics, temporal relationship, and underlying mechanisms of malignancy-associated IgAV are not…
Abstract Number: 0677 • ACR Convergence 2023
Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan
SOKO KAWASHIMA¹, Yoshinori Komagata¹, Mitsumasa Kishimoto² and Shinya Kaname¹, ¹Kyorin University School of Medicine, Tokyo, Japan, ²Kyorin University School of Medicine, Yokohoma, Japan
Background/Purpose: Contrary to Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan or Asian countries. It is possible that therapeutic responses to EGPA with mepolizumab…
Abstract Number: 0711 • ACR Convergence 2023
IgA Vasculitis in a Diverse Adult Patient Population
Michelle Toker¹, Urmi Khanna¹, Roya Nazarian¹, Adhya Mehta², Bibi Ayesha¹, Anand Kumthekar¹ and Benedict Wu¹, ¹Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, ²Jacobi Medical Center, Bronx, NY
Background/Purpose: Immunoglobulin-A (IgA) Vasculitis (IgAV) is a small-vessel vasculitis that is primarily diagnosed based on the European League Against Rheumatism (EULAR) criteria. There is limited…
Abstract Number: 0594 • ACR Convergence 2023
Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease
Panagiotis garantziotis¹, Georgia-Savina Moysidou², stavros doumas³, Dionysis nikolopoulos², Sofia Flouda⁴, Noemin kapsala², Anastasia Filia², George Sentis², Antonis Fanouriakis², George Bertsias⁵ and Boumpas Dimitrios⁶, ¹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁴Unit of Attikon University Hospital, Athens, Greece, ⁵Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece, ⁶National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Despite recent advances, the current state of SLE therapeutics remains largely empirical with existing immunosuppressive treatments failing to induce remission in over 40% of…
Abstract Number: 0652 • ACR Convergence 2023
Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease
Patrick Donio¹, Wesley Fidler², Juan Pablo Diaz-Martinez³, Elvira Bangert⁴, Zareen Ahmad⁵, Medha Soowamber⁶ and Sindhu Johnson⁷, ¹Thunder Bay Regional Health Sciences Centre, Northern Ontario School of Medicine University, Queen's University, Thunder Bay, ON, Canada, ²Northern Ontario School of Medicine, Thunder Bay, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Scleroderma Program, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁶Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Woodbridge, ON, Canada, ⁷Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a multisystem fibrosing autoimmune disease with a high mortality rate. Ethnicity can influence prevalence and disease characteristics in SSc. Less…
Abstract Number: 0588 • ACR Convergence 2023
Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry
Augustine Jose¹, Aishwarya Gopal¹, Mamatha Gorijavolu¹, Anna C Das², Jagan Babu K L¹, Amrita Nayak¹, Chengappa Kavadichanda¹ and Molly Mary Thabah¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²St.Johns National Academy of Health Sciences, Bengaluru, India
Background/Purpose: Rituximab (RTX) is increasingly being employed to treat refractory systemic lupus erythematosus(SLE). Though the drug is effective there is a high risk of adverse…
Abstract Number: 0504 • ACR Convergence 2023
Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature
Wilson Bautista-Molano¹, Linda Ibata², Susan Martinez² and Andrea Chacon², ¹University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²InValue Health Solutions, Bogotá, Colombia
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory pathology that generates a substantial and progressive deterioration of functionality and quality of life. It is associated…
Abstract Number: 0659 • ACR Convergence 2023
Cigarette Exposure in Systemic Sclerosis: Impact on Autoantibody Expression and Disease Manifestations: Analysis of the EUSTAR Cohort
Jacopo Ciaffi¹, Sophie Liem², Saad Ahmed², Eva Hoekstra², Piotr Wiland³, Tatsuya Atsuma⁴, Gabriella Szucs⁵, Alexandra Balbir-Gurman⁶, Laszlo Czirjak⁷, Elisabetta Zanatta⁸, Ina Koetter⁹, Joerg Henes¹⁰, marco Matucci Cerinic¹¹, Paolo Airò¹², Francesco Ursini¹³, Thomas Huizinga² and Jeska de Vries-Bouwstra², ¹IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, ²Leiden University Medical Center, Leiden, Netherlands, ³Wroclaw University of Medicine, Wroclaw, Poland, ⁴Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ⁵University of Debrecen, Department of Rheumatology, Debrecen, Hungary, ⁶Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁷Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, ⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ⁹University Hospital Eppendorf, Prisdorf, Germany, ¹⁰University Hospital Tuebingen, Tuebingen, Germany, ¹¹Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹²Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ¹³IRCCS Istituto Ortopedico Rizzoli, Bologna, Netherlands
Background/Purpose: In rheumatoid arthritis, cigarette smoking confers a risk for anti-CCP positive disease and the risk further increases in smokers carrying specific HLA DRB1-variants. These…
Abstract Number: 0676 • ACR Convergence 2023
Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center
Takashi Yamane¹ and Akira Hashiramoto², ¹Kakogawa Central City Hospital, Kakogawa, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis associated with eosinophil infiltration and Anti-neutrophil cytoplasmic antibody (ANCA) production. Mepolizumab (MPZ), an anti-IL-5 monoclonal…
Abstract Number: 0706 • ACR Convergence 2023
Aortitis and Periaortitis Spectrum in 135 Patients from a Single Referral Centre
Fernando López¹, Javier Loricera², Carmen Secada³, Lucía García-Alcalde⁴, María Núñez-Savar⁴, Ander Ucelay-Aristi⁴ and Ricardo Blanco⁵, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ⁴Department of Cardiovascular Surgery, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Aortitis is the inflammation of the aortic wall, and can be idiopathic or associated with a cluster of infectious and non-infectious diseases (1-3). Periaortitis,…
Abstract Number: 0514 • ACR Convergence 2023
Difficult-to-treat Axial Spondyloarthritis Is Associated with Psoriasis and Comorbidities: Results from a Nationwide Study
Olivier FAKIH¹, Maxime Desmarets², Bérenger Martin², Clément Prati¹, Elisabeth Monnet², Daniel Wendling³ and frank Verhoeven¹, ¹Service de rhumatologie, CHU de Besançon, Besançon, France, ²INSERM CIC-1431, Besançon, France, ³Besançon University Hospital, Besançon, France
Background/Purpose: An increasing number of targeted therapies are available for the treatment of SpA. However, some patients retain active disease despite several lines of treatment.…
Abstract Number: 0708 • ACR Convergence 2023
NFKB1 and NFKBIA: Relevant Players in the Pathogenesis of IgA Vasculitis?
Joao Carlos Batista-Liz¹, Verónica Pulito-Cueto¹, María Sebastián Mora-Gil¹, Belén Sevilla-Pérez², María Teresa Leonardo³, Norberto Ortego-Centeno⁴, Ana Peñalba³, Javier Narvaez⁵, luis martin penagos⁶, Emilio Rodrigo⁶, Lara Belmar-Vega⁶, Cristina Gomez-Fernandez⁷, Luis Caminal-Montero⁸, Paz Collado⁹, Miren Uriarte-Ecenarro¹⁰, Esther Vicente Rabaneda¹¹, Esteban Rubio¹², Manuel León Luque¹², Juan María Blanco-Madrigal¹³, Eva Galindez-Agirregoikoa¹⁴, Santos Castañeda¹⁵, Miguel A Gonzalez-Gay¹⁶, Ricardo Blanco¹⁷ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ³Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Medicine Department, Universidad de Granada, Granada, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁷Division of Dermatology,Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁸Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ⁹Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, ¹⁰Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹²Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹³Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de la Princesa, Madrid, Spain, ¹⁶IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is a B-cell-mediated inflammatory disease. NF-kappa B (NF-kB) plays a key role in autoimmunity and inflammation1. In this regard, the…
Abstract Number: 0601 • ACR Convergence 2023
Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue
Simon Zhou¹, Krishani Kumari Rajanayake², Miao He², Bo Wen², Ankhbayar Lkhagva², Ernie Yap³, Duxin Sun², Jennifer Cross¹, Kory Engelke¹ and Robert B. Huizinga⁴, ¹Aurinia Pharmaceuticals Inc., Rockford, MD, ²University of Michigan, Ann Arbor, MI, ³Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ⁴Reformation Consulting Services, North Saanich, BC, Canada
Background/Purpose: The calcineurin inhibitors (CNI) cyclosporine (CSA) and tacrolimus (TAC) were revolutionary when first introduced for solid organ transplant. Voclosporin (VCS), a novel CNI, is…
Abstract Number: 0615 • ACR Convergence 2023
Prevalence of Barrett’s Esophagus in Patients with Systemic Sclerosis
FNU Rida Ul Jannat¹, Devanshu Verma¹ and Laila Sakkal², ¹West Virginia University Hospital, Morgantown, WV, ²West Virginia University, Morgantown, WV
Background/Purpose: Gastrointestinal manifestations of systemic sclerosis are common and include luminal dysmotility. Esophageal aperistalsis (scleroderma esophagus) presents with dysphagia and reflux; and can predispose patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].